<DOC>
	<DOCNO>NCT01906489</DOCNO>
	<brief_summary>The purpose study evaluate hemoglobin response ( efficacy ) , safety , tolerability orally administer AKB-6548 patient Chronic Kidney Disease ( pre-dialysis ) anemia dose 20 week .</brief_summary>
	<brief_title>20-Week Repeat Oral Dose Study AKB-6548 Subjects With Chronic Kidney Disease Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Key 18 82 year age , inclusive Chronic Kidney Disease GFR category G3aG5 yet dialysis eGFR ≥ 10 ≤ 65 mL/minute/1.73 m2 Anemia secondary CKD ESA status Screening HGB per protocol Iron replete ferritin TSAT level define per protocol Key BMI &gt; 44.0 kg/m2 Red blood cell transfusion within 11 week prior Screening visit Androgen therapy within previous 21 day prior Screening visit Intravenous iron within past 4 week prior Screening visit AST ALT &gt; 1.8x ULN , alkaline phosphatase &gt; 2x ULN , total bilirubin &gt; 1.5x ULN Screening ECG QTc &gt; 500 msec Uncontrolled hypertension Class III IV congestive heart failure Myocardial infarction , acute coronary syndrome , stroke within 6 month prior Screening visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>kidney</keyword>
	<keyword>oral anemia treatment</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>hypoxia-inducible factor</keyword>
	<keyword>HIF</keyword>
	<keyword>hypoxia-inducible factor prolyl-hydroxylase inhibitor</keyword>
	<keyword>HIF-PHI</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>